Schemes between healthcare payers and medical product manufacturers in which the price, level, or nature of reimbursement are tied to future measures of clinical or intermediate endpoints ultimately related to patient quality or quantity of life, appear to have arisen out of a desire to provide patients with access to novel and potentially beneficial healthcare technologies under conditions of significant uncertainty and cost pressures.
Cf. managed entry agreements, Performance Based Agreement and Performance- Linked Reimbursement
Last update: 20 June 2023
Source: PPRI